---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40171403.md"
description: "The gap in performance between defensive big pharma and high-growth biotech was quite noticeable today: Merck rose 1.5%, with Keytruda sales supporting its valuation, and its defensive nature strengthened alongside the high-dividend trend; CSPC Pharmaceutical Group edged up 0.5%, with fundamentals for Hong Kong-listed pharmaceutical companies still okay, moving quietly; WuXi Biologics fell slightly by 1.2%, weighed down by CRO geopolitical pressure. Moderna fell nearly 5%, as its mRNA platform has struggled to find new blockbuster pipelines in the post-COVID era, and market patience is wearing a bit thin 😔"
datetime: "2026-04-24T10:52:26.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40171403.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40171403.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40171403.md)
author: "[主要靠运气](https://longbridge.com/en/profiles/27426993.md)"
---

# The gap in performance between defensive big pharm…


### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)